TYR and neoplasm: However, ATN-658 is the first uPAR antibody to demonstrate consistent robust antitumor effects across a variety of tumor models [22], [26]–[28] that include not only inhibition of invasion and metastasis but also inhibition of proliferation and induction of apoptosis.